Sales & Marketing News | pharmaphorum

News

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

News

The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.

News

A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.

News

FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.

News

More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.

News

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.